Navigation Links
Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions
Date:6/2/2010

NEW YORK, June 2 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) and Epocrates, Inc., today announced a collaboration to give healthcare providers (HCPs) mobile access to the Pfizer Medical Information Group to obtain scientific answers to their product questions or to report an adverse event.  For the first time, clinicians can make direct contact through the Epocrates drug reference app on their iPhone® device to pharmaceutical manufacturers and immediately apply findings to patient care.  Pfizer is enabling easy, direct access to its Medical Information services, via the Epocrates channel, in an effort to enhance the safe and effective use of its medicines, and help improve the quality of patient care.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100602/NY14104-a)

(Photo: http://www.newscom.com/cgi-bin/prnh/20100602/NY14104-b)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100602/NY14104LOGO-c)

"Contact Pfizer" is now a feature available in the Epocrates drug profiles of approximately 40 Pfizer products.  By providing easy access directly to the manufacturer, this feature provides Epocrates' users the option for immediate phone access to Pfizer Medical Information specialists to obtain scientific information about the company's medications and report adverse reactions.  Additionally, healthcare providers will soon have the option to email Pfizer Medical Information for select Pfizer products.

"Healthcare providers have told us they would like direct access to our medical specialists so they can communicate with us in an open, unbiased manner," said Freda C. Lewis-Hall, M.D., FAPA, senior vice president and chief medical officer at Pfizer.  "They expect rapid and tailored scientific responses to their medical questions about our drugs.  Our hope is that the introduction of this new and innovative feature on Epocrates enables doctors and other providers to enhance the care they can provide to their patients using Pfizer medicines."

According to Manhattan Research, 72 percent of doctors currently own smartphones; a number that is expected to increase to four out of five doctors by 2012.  One of their primary uses is to look up prescription drug information at the point of patient care.  Epocrates is the leader in the mobile drug reference and decision support space.  More than 950,000 healthcare professionals, including more than 40 percent of U.S. physicians, actively use Epocrates products, commonly on mobile devices such as iPhone, BlackBerry®, Android™ and Palm®.  

"Epocrates is committed to providing healthcare providers with the resources they need to make the best clinical decisions for their patients at the point of care," said Rose Crane, chief executive officer at Epocrates.  "It is at this 'moment of truth' physicians may have a question only the manufacturer can answer. We are the only company in a position to facilitate that direct link, and significantly advance communication between a manufacturer such as Pfizer and our strong network of HCPs."

The "Contact Manufacturer" feature is initially available to iPhone and iPod touch® device users of the Epocrates application, which includes more than 150,000, or nearly 25 percent, of U.S. doctors.  Epocrates will work to expand the feature to other mobile platforms as its impact on patient care is demonstrated.  As the first company to utilize "Contact Manufacturer," Pfizer helped support the concept and design to ensure the tool was developed to optimally manage physician queries.

About Epocrates, Inc.

Epocrates is a leading provider of clinical information and decision support tools to healthcare professionals.  Epocrates currently has more than 950,000 healthcare professionals, including 40 percent of U.S. physicians and medical students, in its active network.  The company's clinical products and services enable healthcare professionals to make more informed medical decisions, reduce medical errors and practice more efficiently. For more information about Epocrates, please visit www.epocrates.com/company.    

Pfizer Inc:  Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success depends ... instruments for research and understanding the basic principles that were designed to drive ... innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories working ...
(Date:5/24/2017)... ... 24, 2017 , ... Altec Products, Inc., a leader in enterprise ... one-day technology conference in San Diego, CA. , At nVerge 2017, Altec will ... utilize and enhance their Sage ERP solutions by providing improved visibility and control to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. ... NY, who have now spent 10 years as clinical instructors for the reputable ... College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training and ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
Breaking Medicine News(10 mins):